JP2013518037A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518037A5
JP2013518037A5 JP2012549376A JP2012549376A JP2013518037A5 JP 2013518037 A5 JP2013518037 A5 JP 2013518037A5 JP 2012549376 A JP2012549376 A JP 2012549376A JP 2012549376 A JP2012549376 A JP 2012549376A JP 2013518037 A5 JP2013518037 A5 JP 2013518037A5
Authority
JP
Japan
Prior art keywords
growth hormone
seq
hormone compound
single point
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012549376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518037A (ja
JP5980689B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/050909 external-priority patent/WO2011089250A2/en
Publication of JP2013518037A publication Critical patent/JP2013518037A/ja
Publication of JP2013518037A5 publication Critical patent/JP2013518037A5/ja
Application granted granted Critical
Publication of JP5980689B2 publication Critical patent/JP5980689B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012549376A 2010-01-22 2011-01-24 安定な成長ホルモン化合物 Expired - Fee Related JP5980689B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29730510P 2010-01-22 2010-01-22
EP10151405.7 2010-01-22
US61/297,305 2010-01-22
EP10151405 2010-01-22
CNPCT/CN2010/001120 2010-07-23
CN2010001120 2010-07-23
US37860210P 2010-08-31 2010-08-31
US61/378,602 2010-08-31
PCT/EP2011/050909 WO2011089250A2 (en) 2010-01-22 2011-01-24 Stable growth hormone compounds

Publications (3)

Publication Number Publication Date
JP2013518037A JP2013518037A (ja) 2013-05-20
JP2013518037A5 true JP2013518037A5 (cg-RX-API-DMAC10.html) 2014-03-06
JP5980689B2 JP5980689B2 (ja) 2016-08-31

Family

ID=44166478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549376A Expired - Fee Related JP5980689B2 (ja) 2010-01-22 2011-01-24 安定な成長ホルモン化合物

Country Status (11)

Country Link
US (1) US9211342B2 (cg-RX-API-DMAC10.html)
EP (1) EP2525833A2 (cg-RX-API-DMAC10.html)
JP (1) JP5980689B2 (cg-RX-API-DMAC10.html)
AU (1) AU2011208620B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012018162A2 (cg-RX-API-DMAC10.html)
CA (1) CA2787895A1 (cg-RX-API-DMAC10.html)
IL (1) IL220648A0 (cg-RX-API-DMAC10.html)
MX (1) MX338357B (cg-RX-API-DMAC10.html)
RU (1) RU2012134974A (cg-RX-API-DMAC10.html)
WO (1) WO2011089250A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201205385B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
CN103269720A (zh) * 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
JP2016511275A (ja) 2013-03-11 2016-04-14 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
EP3079722B1 (en) 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Method for thioether conjugation of proteins
MY193776A (en) 2015-09-22 2022-10-27 Univ California Modified cytotoxins and their therapeutics use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
WO2017055582A1 (en) 2015-10-01 2017-04-06 Novo Nordisk A/S Protein conjugates
KR20180003677A (ko) * 2016-06-30 2018-01-10 주식회사 크레아플래닛 인간 성장호르몬 변이 단백질 또는 이의 트랜스페린 융합 단백질을 유효성분으로 포함하는 약학적 조성물

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
EP0355460B1 (en) 1988-08-24 2000-12-27 American Cyanamid Company Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
ATE193541T1 (de) 1989-03-20 2000-06-15 Gen Hospital Corp Insulinotropes hormon
US5101018A (en) 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
ES2113879T3 (es) 1990-01-24 1998-05-16 Douglas I Buckley Analogos de glp-1 utiles para el tratamiento de diabetes.
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
JP3267293B2 (ja) * 1990-12-03 2002-03-18 ジェネンテク，インコーポレイテッド 改変された結合性を有する変異タンパク質の豊富化法
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
EP0555649B1 (en) 1992-01-14 2004-12-08 Ajinomoto Co., Inc. Gene encoding transglutaminase derived from fish
DK0955062T3 (da) 1992-07-31 2007-09-17 Genentech Inc Vandig formulering indeholdende humant væksthormon
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5736356A (en) 1994-01-28 1998-04-07 Ajinomoto Co., Inc. Transglutaminase originating from Crassostrea gigas
EP0777726B1 (en) 1994-08-26 2006-06-07 Novozymes A/S Microbial transglutaminases, their production and use
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
ATE248219T1 (de) 1995-01-19 2003-09-15 Novozymes As Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
US20020077461A1 (en) 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6620916B1 (en) 1996-09-26 2003-09-16 Ajinomoto Co., Inc. Modified physiologically active proteins and medicinal compositions containing the same
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
JPH1156378A (ja) * 1997-06-11 1999-03-02 Nippon Chem Res Kk 変異型ヒト成長ホルモンとその用途
AU747179B2 (en) 1997-06-25 2002-05-09 Merck Serono Sa Disulfide cross-linked glycoprotein hormone analogs, their preparation and use
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
JPH1192499A (ja) * 1997-09-22 1999-04-06 Sumitomo Pharmaceut Co Ltd ヒト成長ホルモン変異体
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
AU2712899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
JP2002508162A (ja) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU5805500A (en) 1999-07-07 2001-01-30 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
NZ522847A (en) * 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
JP2004524020A (ja) * 2001-01-11 2004-08-12 マキシゲン・エイピーエス 改良された成長ホルモン分子
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1421539B1 (en) * 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
WO2003013573A1 (en) 2001-08-10 2003-02-20 Epix Medical, Inc. Polypeptide conjugates with extended circulating half-lives
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
AU2002341215A1 (en) 2001-11-12 2003-05-26 University Of Wales College Of Medicine Growth hormone variations in humans and their uses
OA13063A (en) 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
FR2836382B1 (fr) 2002-02-28 2004-08-13 Biomerieux Sa Nouveaux agents de couplages, leurs conjugues, ainsi que l'utilisation de ces conjugues dans des methodes de diagnostic
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
BR0308904A (pt) 2002-04-10 2005-05-03 Lilly Co Eli Método de tratamento de gastroparesia, e, uso de um composto de glp-1
DE60334983D1 (de) 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
EP2067483A1 (en) 2003-02-19 2009-06-10 Ipsen Pharma Analogues of GLP-1
AU2004235872A1 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
WO2005035553A2 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
JP2007537141A (ja) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ 新規なｇｌｐ−１化合物
CN101665538A (zh) 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
ES2383994T3 (es) 2004-04-07 2012-06-28 Ares Trading S.A. Formulación líquida de hormona del crecimiento
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
US20090176967A1 (en) 2004-08-02 2009-07-09 Novo Nordisk Healthcare A/G Conjugation of FVII
JP2008515856A (ja) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１化合物
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP1863537A2 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Dimeric peptide agonists of the glp-1 receptor
ES2484796T3 (es) 2005-03-18 2014-08-12 Novo Nordisk A/S Compuestos de GLP-1 extendidos
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
JP2009504170A (ja) 2005-08-18 2009-02-05 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
AU2007215566A1 (en) * 2006-01-19 2007-08-23 Ambrx, Inc. Non-natural amino acid polypeptides having modulated immunogenicity
US20090082254A1 (en) 2006-02-14 2009-03-26 Novo Nordisk A/S Coupling of Polypeptides at the C-Terminus
WO2008003750A2 (en) 2006-07-07 2008-01-10 Novo Nordisk Health Care Ag New protein conjugates and methods for their preparation
ES2745411T3 (es) 2006-07-27 2020-03-02 Wang Nai Fang Compuestos y composiciones de arilsulfanilo para administración de agentes activos
JP2010500885A (ja) 2006-08-18 2010-01-14 ノボ ノルディスク ヘルス ケア アーゲー 改善された特異性を有するトランスグルタミナーゼ変異体
EP2059260B1 (en) 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
WO2008101240A1 (en) 2007-02-16 2008-08-21 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
WO2008112836A2 (en) 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
WO2010029107A1 (en) 2008-09-09 2010-03-18 Novo Nordisk Health Care Ag Growth hormone conjugate with increased stability
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
JP5816097B2 (ja) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
ES2582590T3 (es) 2010-02-16 2016-09-13 Novo Nordisk A/S Método de purificación

Similar Documents

Publication Publication Date Title
FI3727426T3 (fi) Inkretiinianalogeja ja niiden käyttötarkoituksia
RU2012134974A (ru) Стабилизированное соединение гормона роста
NZ608502A (en) Polypeptides that bind to human complement component c5
JP2011173914A5 (cg-RX-API-DMAC10.html)
WO2009033665A3 (en) Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
WO2012122340A8 (en) Soluble guanylate cyclase activators
WO2009033711A3 (en) Use of glp-1 as a therapeutic agent
WO2009033793A3 (en) Pentagastrin as a therapeutic agent
WO2009040036A3 (en) Use of a galanin peptide as a therapeutic agent
JP2016523891A5 (cg-RX-API-DMAC10.html)
AR081427A1 (es) Metodo para preparar anticuerpos con propiedades mejoradas
JP2013530974A5 (cg-RX-API-DMAC10.html)
RU2012157683A (ru) Производные инсулина, содержащие дополнительные дисульфидные связи
WO2009046847A3 (en) Use of peptide ll-37 as a therapeutic agent
WO2011080102A3 (en) Glp-1 analogues and derivatives
WO2009043463A3 (en) Use of gluten exorphin c : as a therapeutic agent
JP2012515748A5 (cg-RX-API-DMAC10.html)
PE20130222A1 (es) Activadores de guanilato ciclasa soluble
WO2009033760A3 (en) Use of fibronectin fragment (196-203 ) as a therapeutic agent
WO2009033667A3 (en) Use of a peptide as a therapeutic agent
WO2009033681A3 (en) Cyclo-argd as a therapeutic agent
NZ599604A (en) Synthetic myostatin peptide antagonists
PH12018502465A1 (en) Mic-1 compounds and use thereof
WO2009033737A3 (en) Use of gluten exorphin c : as a therapeutic agent
JP2013530702A5 (cg-RX-API-DMAC10.html)